

**Table 5** Pathological outcomes of patients with resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy.

Characteristics	UFS group (n = 37)	GS group (n = 38)	<i>P</i>
Tumor size (mm)	25 (15–90)	22 (15–50)	0.002
T (T1/T2/T3)*	4/27/6	12/24/2	0.046
LN metastasis (+)	29 (78%)	18 (47%)	0.006
Number of dissected LNs	20 (6–49)	17 (3–69)	0.454
Number of metastatic LNs	1 (0–11)	1 (0–12)	0.017
LN ratio	0.122 (0–0.563)	0.033 (0–0.706)	0.014
Stage (Ia/Ib/IIa/IIb/III)*	0/7/1/19/10	9/12/0/12/6	0.012
Histology (wel/mod/por/other)	10/23/1/3	15/16/5/2	0.164
Lymphatic invasion (+)	33 (89%)	27 (71%)	0.050
Venous invasion (+)	35 (95%)	34 (89%)	0.414
Neuronal invasion (+)	29 (78%)	35 (92%)	0.093
Portal vein invasion** (+)	6 (16%)	2 (5%)	0.122
Residual tumor (R1)	6 (16%)	2 (5%)	0.122
Pathological response <sup>†</sup> (I/IIa/IIb/III)	n.a.	9/24/4/1	n.a.

Data are expressed as median (range)

\*AJCC 8<sup>th</sup> edition <sup>†</sup>Evans' classification \*\*Invasion to portal vein or superior mesenteric vein or splenic vein

GS gemcitabine plus S-1, LNs lymph nodes, Mod moderately, Por poorly, SF surgery first, Wel well.